O’Melveny’s Pharmaceuticals Group works with clients to create and implement business and legal strategies that promote and protect innovation, drive growth, and secure market position.
We feature a litigation team with unparalleled experience handling high-stakes, complex litigation for pharmaceutical industry clients. Our team is renowned for devising cutting-edge defenses in the class action, mass tort, products liability, and intellectual property cases most often faced by pharmaceutical companies. Law firm rankings publication The Legal 500 praises our pharmaceutical industry litigators, describing them as “uniformly excellent,” and our results speak for themselves—we serve as one of Merck’s national counsel in Vioxx litigation, and we are lead counsel for Amylin in product liability suits relating to diabetes drug Byetta.
Our corporate team provides seasoned, sophisticated counseling on governance matters as well as on the strategic transactions—including acquisitions, joint ventures, commercial partnerships, licensing agreements, and technology transfers—that often unlock growth potential for pharmaceutical companies. We are also experienced in advising on capital-raising transactions, from the venture capital and private equity-backed growth financings of innovative startups to multi-billion dollar public offerings of global corporations.
For more information, visit our
Capital Markets,
Intellectual Property & Technology,
Mergers & Acquisitions,
Products Liability, and
Venture Capital and Emerging Technologies Practice pages.